Intelligence Feed event · Equity · 2026-09-24

    InnoCare and Eli Lilly enter multi-target discovery pact worth up to $3.35 billion

    Question

    InnoCare and Eli Lilly enter multi-target discovery pact worth up to $3.35 billion

    Direct answer

    InnoCare Pharma announced a research collaboration and licensing pact with Eli Lilly targeting the discovery and development of compounds across up to five therapeutic targets. Under the structure, InnoCare secures up to $100 million in upfront and near-term cash payments, with additional potential milestone considerations reaching $3.25 billion upon achieving specified development and commercial milestones.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-24
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “InnoCare and Eli Lilly enter multi-target discovery pact worth up to $3.35 billion”, revision 1, evidence through 2026-09-24. https://marketontology.com/market-events/2026-09-24/innocare-and-eli-lilly-enter-multi-target-discovery-pact-worth-up-to-3-35-billio-3e0602

    EQUITY
    InnoCare and Eli Lilly enter multi-target discovery pact worth up to $3.35 billion
    InnoCare Pharma announced a research collaboration and licensing pact with Eli Lilly targeting the discovery and development of compounds across up to five therapeutic targets. Under the structure, InnoCare secures up to $100 million in upfront and near-term cash payments, with additional potential milestone considerations reaching $3.25 billion upon achieving specified development and commercial milestones.
    LLY
    Impact
    71
    SEP 24
    SIG
    88%
    LLY
    InnoCare and Eli Lilly enter multi-target discovery pact worth up to $3.35 billion
    InnoCare Pharma announced a research collaboration and licensing pact with Eli Lilly targeting the discovery and development of compounds across up to five therapeutic targets. Under the structure, InnoCare secures up to $100 million in upfront and near-term cash payments, with additional potential milestone considerations reaching $3.25 billion upon achieving specified development and commercial milestones.
    → Capital deployment of up to $100 million upfront by Eli Lilly accelerates target discovery pipeline assets while capping early-stage R&D risk through milestone structures.
    Impact
    InnoCare Pharma announced a research collaboration and licensing pact with Eli Lilly targeting the discovery and development of compounds across up to five therapeutic targets. Under the structure, InnoCare secures up to $100 million in upfront and near-term cash payments, with additional potential milestone considerations reaching $3.25 billion upon achieving specified development and commercial milestones.
    Affected
    LLY
    Transmission
    Capital deployment of up to $100 million upfront by Eli Lilly accelerates target discovery pipeline assets while capping early-stage R&D risk through milestone structures.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYpipeline expansion through multi-target biopharma licensingUp1-3mInnoCare Pharma entered into a strategic research collaboration and license agreement with Eli Lilly to discover and develop compounds against up to five targets.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month